Q-omics provides the consensus-scored AOX1 profile across patient tissues and cancer cell-line models. AOX1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AOX1 is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, AOX1 protein abundance shows 27,782 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where AOX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AOX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AOX1 survival associations across molecular data types. AOX1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AOX1 RNA expression–survival associations across cancer types. High AOX1 expression shows unfavorable associations in LGG and BLCA, but favorable associations in KIRC, SKCM, HNSC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AOX1 RNA expression.
This table summarizes AOX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for AOX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AOX1 shows lower tumor expression in BLCA, THCA, KIRP, LUAD, COAD and LUSC. The BLCA box plot shows higher AOX1 RNA expression in normal versus tumor tissue (log2 FC = −4.317, t-test p < 0.001).
This table shows molecular features associated with AOX1 in patient tissues and cancer cell lines. In patient samples, AOX1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, AOX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
